Rezolute, Inc.

Stocks

RZLT

US76200L3096

Market Closed - Nasdaq 16:00:00 2026-10-28 EDT			5-day change	1st Jan Change
4.220 ^USD	+2.68%		+14.05%	+78.81%

10-14	Rezolute Says Phase 3 upLIFT Study Fully Enrolled, Topline Data Due Mid-December	MT
10-14	Rezolute, Inc. Completes Enrollment In Phase 3 upLIFT Study Of Ersodetug In Tumor Hyperinsulinism	CI

Transcript : Rezolute, Inc. - Special Call

Published on 12/11/2025 at 02:05 pm EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to the sunRIZE Topline Data Conference Call. [Operator Instructions] Please note, this event is being recorded.

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Latest news about Rezolute, Inc.

10-14	Rezolute Says Phase 3 upLIFT Study Fully Enrolled, Topline Data Due Mid-December	MT
10-14	Rezolute, Inc. Completes Enrollment In Phase 3 upLIFT Study Of Ersodetug In Tumor Hyperinsulinism	CI
10-06	Cantor Fitzgerald Upgrades Rezolute to Overweight From Neutral	MT
10-05	Rezolute, Inc. Announces Fda Recommendation to Hold A Pre-Bla Meeting as A Precursor to Submitting A Biologics License Application for Congenital Hyperinsulinism	CI
10-05	Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment	MT
09-29	Craig-Hallum Upgrades Rezolute to Buy From Hold, Price Target is $7	MT
09-24	Rezolute Fiscal Q4 Loss Narrows	MT
09-24	Rezolute, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended June 30, 2026	CI
09-09	Rezolute Says FDA Still Reviewing Ersodetug Data From Phase 3 Congenital Hyperinsulinism Study	MT
09-09	Rezolute Provides Update on FDA Review of Its Phase 3 Sunrize Study Results in Congenital Hyperinsulinism	CI
08-25	Rezolute Shares to Show Strength Towards Upcoming Ersodetug Catalysts, Wedbush Says	MT
06-17	Rezolute, Inc. Highlights Results from Natural History Outcomes Studies and Its Ersodetug Clinical Program in Hyperinsulinism At Annual Meeting of the Endocrine Society	CI
06-03	Wedbush Adjusts Price Target on Rezolute to $6 From $5, Maintains Outperform Rating	MT
06-02	Rezolute Shares Rise After Participants Meet Responder Criterion in Phase 3 Tumor Hyperinsulinism Trial	MT
06-02	Rezolute, Inc. Provides Positive Interim Data For Its Phase 3 UpLIFT Study Of Ersodetug In Tumor Hyperinsulinism	CI

Chart Rezolute, Inc.

Duration

Period

RZLT: Dynamic Chart

Company Profile

Sector

More about the company

Income Statement and Estimates

Projected Income Statement - Annual - Rezolute, Inc.

More financial data

Ratings

More Ratings

EPS Estimates

Evolution of Analysts' Estimates - EPS - Rezolute, Inc.

Revisions to estimates